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Abstract
Female sexual dysfunction occurs frequently in midlife breast cancer survivors (BCS) and encompasses problems
with sexual desire, interest, arousal, orgasm and genitopelvic pain. Although common, sexual problems are
under-diagnosed and under-treated in BCS. The objective of this review was to assess primary studies that
intervene on sexual dysfunction in BCS. In February 2015, PubMed, SCOPUS, CINAHL, COCHRANE and Web of
Science databases were systematically searched for randomized controlled clinical trials (RCTs) of vaginal (lubricants,
moisturizers, estrogens, dehydroepiandrosterone [DHEA], testosterone, vibrators, dilators), systemic (androgens,
anti-depressants, flibanserin, ospemifene), physical therapy (physical activity, pelvic floor training), counseling and
educational interventions on sexual function in BCS. Observational studies of vaginal interventions were also
included due to the paucity of RCTs. The search yielded 1414 studies, 34 of which met inclusion criteria. Both
interventions and outcomes, measured by 31 different sexual function scales, were heterogeneous, and therefore
data were not pooled. The review found that regular and prolonged use of vaginal moisturizers was effective in
improving vaginal dryness, dyspareunia, and sexual satisfaction. Educational and counseling interventions targeting
sexual dysfunction showed consistent improvement in various aspects of sexual health. No consistent improvements in
sexual health were observed with physical activity, transdermal testosterone or hot flash interventions. There was a lack
of BCS-specific data on vaginal lubricants, vibrators, dilators, pelvic floor therapy, flibanserin or ospemifene. Overall, the
quality of evidence for these studies was moderate to very low. Because each of the interventions with BCS data
had limited efficacy, clinical trials to test novel interventions are needed to provide evidence-based clinical
recommendations and improve sexual function in BCS.
Keywords: Breast cancer, Female sexual dysfunction, Systematic review, Cancer survivorship, Vaginal
interventions, Sexual health
Introduction
In the United States, there are more than 2.3 million fe-
male cancer survivors who are younger than age 60;
40 % of these women are survivors of breast cancer [1].
Most midlife breast cancer survivors (BCS) undergo sur-
gery, chemotherapy, radiation and/or endocrine therapy
for cancer treatment. Receiving a breast cancer diagnosis
and undergoing associated treatments including long
term endocrine therapy can impair sexual function via a
number of mechanisms, including disrupting ovarian
function, body image, intimacy and relationships [2–7].
In turn, impaired sexual function contributes to lower
quality of life in survivorship [8, 9].
Female sexual dysfunction has been classified into
three categories: sexual interest or arousal disorder, or-
gasmic disorder, and genitopelvic pain or penetration
disorder. A women is diagnosed with sexual dysfunction
if she experiences persistent symptoms that last at least
six months and cause marked distress, as detailed in the
Diagnostic and Statistical Manual 5th Edition (DSM-5)
[10] (Table 1). A population-based cohort study of
recently diagnosed BCS showed 65 % reported that they
were sexually active; 52 % of sexually active women
described problems with two or more areas of sexual
function [11]. At 5 and 10 years after cancer diagnosis,
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prevalence of sexual problems remained significant, 26
and 19 %, respectively [12]. These findings that BCS are
sexually active and experience sexual dysfunction that
persists throughout survivorship have been replicated in
multiple cohorts [9, 13–15].
Sexual health is often under-addressed in survivorship
care, and only a minority of BCS receives information
and education about sexual function from oncology pro-
fessionals [16]. Among primary care providers at a
university-based medical center, 62 % self-reported never
or rarely discussing sexual issues with cancer survivors
[17]. Providers who perceived having adequate prepared-
ness to evaluate late effects or formal training in sur-
vivorship care were more likely to address sexual health
considerations. Conversely, lack of knowledge in health-
care providers was a significant barrier to discussions on
sex [18]. Moreover, patients may be reluctant or embar-
rassed to raise sexual concerns with healthcare providers
[19]. Only 50 % of BCS thought their providers were
knowledgeable about cancer care follow-up and even
fewer (41 %) felt that their providers were equipped to
treat their cancer therapy-related symptoms [20]. Hence,
disseminating evidence-based information on managing
sexual concerns to healthcare providers is a critical as-
pect of improving sexual health care after breast cancer.
Multiple pharmacologic and behavioral treatments
have been tested to improve sexual health after breast
cancer. We present a systematic review of primary re-
search on managing sexual dysfunction in breast cancer
survivors to generate evidence-based content for im-




This systematic review was conducted in accordance
with PRISMA guidelines [21]. In February 2015, we sys-
tematically searched the following databases: PubMed
(1966 – February 2015), SCOPUS (1966 – February 2015),
CINAHL (Cumulative Index to Nursing and Allied Health
Literature) (1981 – February 2015), COCHRANE (all
years), and Web of Science (1900 – February 2015). We
screened the bibliographies of all included studies for add-
itional references. We sought peer-reviewed articles exam-
ining interventions on sexual health among female BCS.
We included studies on female breast cancer patients with-
out age restriction and excluded studies on males, non-
humans and other female cancer patients. We included
studies on sexual dysfunction, including problems with
dyspareunia, sexual pain, vaginismus, vaginal dryness, sex-
ual arousal, desire, and orgasm. For types of interventions,
we included vaginal (lubricants, moisturizers, estrogens,
dehydroepiandrosterone [DHEA], testosterone, vibrators
and dilators), systemic (androgens, anti-depressants, fliban-
serin, ospemifene), physical therapy (physical activity,
pelvic floor training), counseling and educational interven-
tions. We did not include studies on systemic estrogen in-
terventions. For physical therapy, systemic, and counseling
Table 1 Female sexual dysfunction classification and diagnostic criteria from the Diagnostic and Statistical Manual of Mental
Disorders, Fifth Edition [10]
Disordera Criteria
Female sexual interest or arousal disorder Absent or significantly decreased sexual interest or arousal as manifested by a lack of or reduction in:
1. Sexual activity
2. Sexual or erotic thoughts or fantasies
3. Initiation of sexual activity and unreceptive to partner’s attempts to initiate
4. Sexual excitement or pleasure during sexual activity in at least 75 % of all sexual encounters
5. Sexual interest or arousal in response to any internal or external sexual or erotic cues (written, verbal, or
visual)
6. Genital or non-genital sensations during sexual activity in at least 75 % of all sexual encounters
Female orgasmic disorder Presence of either of the following in at least 75 % of all sexual activities:
1. Significant delay in, frequency of, or absence of orgasm
2. Significantly reduced intensity of orgasmic sensations
Genitopelvic pain or penetration disorder Persistent or recurrent difficulties with one or more of the following:
1. Vaginal penetration during intercourse
2. Significant vulvovaginal or pelvic pain during intercourse or penetration attempts
3. Significant fear or anxiety about vulvovaginal or pelvic pain in anticipation of, during, or because of
vaginal penetration
4. Significant tensing or tightening of pelvic floor muscles during attempted vaginal penetration
aSymptoms must persist for at least 6 months, cannot be attributed to another nonsexual mental disorder, are not related to or a result of relationship distress or
other significant life stressors, and are not a consequence of the effects of a substance, medication, or other medical conditions
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and educational interventions, we included only random-
ized controlled clinical trials (RCTs). We retained RCTs
and observational studies (cohort and case control studies)
on vaginal interventions due to the dearth of RCTs. We ex-
cluded qualitative studies and case reports. The final
PubMed search strategy is detailed in the Appendix.
Outcome measures
The primary outcome of this systematic review was sex-
ual function. Measures of sexual function varied widely
among studies and are summarized in Table 2.
Data collection
Three review authors (SS, SD, IS) independently screened
the titles and abstracts of all search citations using the
inclusion and exclusion criteria. Discrepancies among
authors were resolved via consensus. Two of the three re-
view authors (SS, SD, or IS) independently abstracted data
on included articles. Data extracted included participants,
interventions, sexual health outcome measures, results,
and risks of bias (randomization, allocation concealment,
blinding, sample size and analysis approach).
Risk of bias for all included studies was assessed inde-
pendently by two review authors (SD and IS) using the
Cochrane risk of bias assessment tool [22]. Discrepan-
cies were resolved by discussion. Studies were evaluated
for the following: selection bias (random sequence gen-
eration and allocation concealment); performance blind-
ing (blinding of participants and personnel); detection
bias (blinding of outcome assessment); attrition bias (in-
complete outcome data); reporting bias (selective report-
ing); and other bias. Each bias criteria was assigned a
high, low or unclear risk of bias rating. Additionally, we
evaluated the quality of each study using the following
GRADE criteria: study limitations (i.e., risk of bias);
consistency of effect; imprecision; indirectness and pub-
lication bias. RCTs were first classified as high quality,
and observational studies were first classified as low
quality. All studies were downgraded in quality for any
of the following problems: serious limitation to study
quality; important inconsistency; uncertainty about dir-
ectness; imprecise or sparse data; or high probability of
reporting bias.
Results
After searching PubMed (n = 637), SCOPUS (n = 665),
CINAHL (n = 276), COCHRANE (n = 220) and Web of
Science (n = 186) and hand picking (n = 14), 1984 articles
were retrieved, leaving 1414 articles after removing
duplicates. Forty-two full-text articles were accessed,
from which 8 were excluded, leaving 34 articles included
in this review. The PRISMA flow diagram details study
selection results (Fig. 1). No article was excluded be-
cause of non-English language.
A total of 31 different sexual health outcome measures
were used to assess intervention effects across the 34 pa-
pers (Table 2). The Female Sexual Function Index (n =
4 studies) and Cancer Rehabilitation Evaluation System
(n = 3 studies) were the most commonly used measures.
The Vaginal Maturation Index, Vaginal Health Index,
and Sexual Activity Questionnaire were each used in 2
separate studies. All other outcome measures were used
by single studies. Because of heterogeneity in both inter-
vention and outcome measures, we were unable to pool
estimates for a meta-analysis or derive strengths of rec-
ommendations based on the GRADE approach.
Vaginal products interventions
We searched for studies on vaginal lubricants, moistur-
izers, estrogens, DHEA, testosterone, vibrators and dila-
tors. Eleven studies met inclusion criteria (Tables 3 and 4,
Fig 2a). No studies were found on lubricants, DHEA, vibra-
tors and dilators. There were 3 RCTs and 8 single-arm pro-
spective cohorts with no controls. All participants had
genitourinary symptoms, experienced ≥ 6 months of amen-
orrhea, and completed primary breast cancer treat-
ment. The studies occurred in Australia, Belgium,
Germany, Italy, Korea, and the United States. The
polycarbophil-based moisturizer Replens® was tested in
4 studies involving 133 participants, one in combin-
ation with olive oil and pelvic floor muscle relaxation
[23–26]; compounded testosterone cream was tested in
2 studies involving 34 participants [27, 28]; pH balanced
lactic acid gel was used in 1 study of 98 participants [29];
and vaginal estrogens were used in 5 studies involving 47
participants [24, 30–33]. Outcomes included patient-
reported vaginal symptoms, such as dryness, dyspareunia
and itching, and vaginal exam-based pH and cytology.
In women using Replens®, vaginal dryness decreased in
the first week of use [23], with significant additional im-
provement in dryness, dyspareunia, sexual satisfaction
and frequency by 4 and 12 weeks of use [23, 25, 26].
Compared with local vaginal estrogens (estriol or estra-
diol), Replens® appeared less effective at decreasing
vaginal symptoms and improving vaginal histology.
However, women who used vaginal estrogens experi-
enced an increase in their serum estradiol levels or
decline in gonadotropins, both evidence of systemic
absorption [24, 30–33]. At steady state, women on aro-
matase inhibitors using 25 microgram estradiol tablets
twice weekly had low levels of serum estradiol (median
1.3 pg/mL) [33]. However, 12 h after insertion of the tablet,
median peak estradiol reached approximately 28 pg/mL
[33]. A pH-balanced gel (pH 4.0) decreased vaginal dryness
and dyspareunia more than the placebo gel with a higher
pH [29]. Across products, vaginal irritation occurred in
12-50 % of participants, but whether this symptom per-
sisted was not well described.
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Table 2 Sexual function outcome measures
Assessment descriptiona Scoring rubric
Arizona Sexual Experience Scale (ASEX) [68, 69] 5-item scale measuring sexual drive, arousal,
vaginal lubrication, orgasm, and satisfaction
• 6-point Likert scale (1 – 6); total score 5 – 30
• Higher scores indicate greater sexual
dysfunction.
• Score > 19 indicates sexual dysfunction.
Body Image Relationships Scale (BIRS) [70] 11-item Appearance and Sexuality Subscale
measuring satisfaction with sexual activity, physical
appearance, and body image
• 5-point scale (1 – 5); total score 11 – 55
• Higher scores indicate greater impairment.
Cancer Rehabilitation Evaluation System
(CARES) [71]
Includes 4-item Sexual Interest, 4-item Sexual
Function, and 18-item Marital Issues Subscales
• 5-point scale (0 – 4)
• Higher scores indicate greater impairment.
Changes of Sexual Functioning Questionnaire
(CFSQ) [72]
Includes 3-item Desire/Interest, and 2-item
Frequency/Pleasure Subscales
• 5-point Likert scale (1 – 5); total score 5 – 25
• Higher scores indicate lesser impairment.
Derogatis Inventory of Sexual Functioning
(DISF-SR) [73]
4-item subscale measuring sexual drive and
relationship satisfaction
• 5- or 9-point scale (depending on item)
• Higher scores indicate less impairment.
EORTC Quality of Life Questionnaire (QLQ)
Breast Cancer Module [74]
23-item Sexual Function and Body Image
Subscales measuring breast cancer therapy side
effects
• 4-point rating scale; total score 0 – 100 (after
linear transformation)
• Higher scores indicate less impairment.
Female Sexual Function Index (FSFI) [75] 19-item scale measuring sexual desire, arousal,
lubrication, orgasm, satisfaction, and pain
• 6-point Likert scale (0 – 5); total score 0 – 36
• Higher scores indicate better sexual function.
• Score < 26.5 suggests sexual dysfunction.
Functional Assessment of Cancer Therapy
(FACT) [76]
18-item Endocrine Symptoms Subscale (FACT-ES)
measuring hormone-related/ menopausal
symptoms of breast cancer
• Total score 0 – 72
• Higher scores indicate fewer symptoms.
Marital Intimacy Questionnaire [77] 8-item scale measuring marital intimacy • 4-point Likert scale (1 – 4); total score 8 – 32
• Higher scores indicate less impairment.
Medical Outcomes Study [78] 4-item Sexual Functioning Subscale measuring
sexual dysfunction symptoms
• 6-point Likert scale (1 – 6)
• Higher scores indicate more symptoms.
Menopausal Sexual Interest Questionnaire
(MSIQ) [79]
10-item Sexual Satisfaction Subscale measuring
desire, responsiveness, and satisfaction in
postmenopausal women
• 7-point Likert scale (1-7); total score 10 - 70
• Higher scores indicate less impairment.
Menopausal Symptom Score [80] Adapted 7-item scale measuring study-specific
menopausal symptoms
• 5-point Likert scale (0 – 4); total score 0 – 28
• Higher scores indicate more symptoms.
Profile of Female Sexual Function (PFSF) [81] 37-item scale measuring sexual desire, arousal,
orgasm, pleasure, concerns, responsiveness, and
self-image
• 5-point Likert scale (1 – 5); total score 0 – 100
(after linear transformation)
• Higher scores indicate less impairment.
Psychological Adjustment to Illness Scale
(PAIS) [82]
46-item clinical interview with Sexual Relationships
(PAIS-SR) and Sexual Problems Subscales
measuring psychological and social adjustment to
illness
• 4-point scale (0 – 3)
• Higher scores indicate poorer adjustment.
• Score < 35 = good; 35-51 = fair; > 51 = poor
Quality of Marriage Index (QMI) [83] 6-item scale measuring marital quality • 7-point bipolar scale (1 – 7); total score 6 – 42
• Higher scores indicate better quality of
marriage.
Study-Specific Scales [50] Study-specific scales measuring frequency of
sexual desire, intercourse, masturbation, orgasm,
initiative for sex, and relationship satisfaction
• Higher scores indicate less impairment.
Study-Specific Scales [51] Study-specific items measuring sexual satisfaction,
relationship satisfaction, dyspareunia, and comfort
with sexuality
• 5- or 6-point Likert scale (depending on item)
• Higher scores indicate less impairment.
Sexual Activity Questionnaire (SAQ) [84] 10-item scale with 3 main subscales measuring:
Pleasure (SAQ-P; desire, enjoyment, satisfaction),
Discomfort (SAQ-D; vaginal dryness, dyspareunia),
Habit Subscale (SAQ-H; frequency)
• 4-point Likert scale (0 – 3); total score 0 – 24
• Higher scores indicate less impairment.
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Two studies without control participants intervened
with vaginal compounded testosterone in BCS on aro-
matase inhibitors [27, 28]. Compared to baseline mea-
sures, 4 weeks of vaginal testosterone improved all
domains of the Female Sexual Function Inventory (FSFI)
and vaginal atrophy symptoms. One study found 10 %
(n = 2) of women had detectable serum estradiol levels
after testosterone, though both estradiol levels were very
low, <8 pg/mL [28].
Systemic therapy interventions
We sought studies using systemic androgens, anti-
depressants, ospemifene and flibanserin to intervene on
sexual function (Tables 5 and 6, Fig 2b). No studies on
ospemifene or flibanserin were found. Three randomized,
double-blind cross-over trials on androgens and anti-
depressants were included. All participants completed pri-
mary cancer treatment. The studies were conducted in
Brazil, Netherlands, and the United States. In the single
study on applying daily testosterone cream to the skin for
one month, testosterone in postmenopausal cancer survi-
vors did not result in greater sexual desire, pleasure or
function than placebo cream [34]. This study accepted all
cancer types, with 73 % of the 150 participants on tamoxi-
fen or aromatase inhibitor, suggesting that they are breast
cancer survivors. No increases in estradiol were noted
while on testosterone cream, consistent with prior studies
in women without history of breast cancer [35–40]. Two
additional trials involving 115 participants intervened on
hot flashes as the primary outcome with venlafaxine,
Table 2 Sexual function outcome measures (Continued)
Sexual Desire Subscale of Brief Index of Sexual
Function (BISF) [85]
Includes 8-item Sexual Desire and 9-item Sexual
Arousal Subscales
• 6- or 7-point Likert scale (0 – 5 or 0 – 6)
• Higher scores indicate less impairment.
Sexual Dysfunction Scale [57] 25-item study-specific scale with 3 subscales
measuring: Behavioral (vaginal dryness, dyspar-
eunia, and frequency), Evaluative (interest, arousal,
and satisfaction), Body image (sense of attractive-
ness, impact of weight change and hair loss)
• Total score 0 – 100
• Higher scores indicate less impairment.
Sexual Function Subscale of Greene
Climacteric Scale (GCS) [86]
21-item scale with 4 subscales measuring:
Vasomotor Symptoms (2 items), Somatic
Symptoms (7 items; headaches and muscle/joint
pains), Psychological Symptoms (11 items), Sexual
Function (1 item; sexual interest)
• 4-point scale (0 – 3); total score 0 – 6 (vaso-
motor), 0 – 21 (somatic), 0 – 33 (psychological),
0 – 3 sexual function; combined total score 0 –
63
• Higher scores indicate more symptoms.
Sexual Problems Frequency [45] Adapted subscale from BIRS measuring frequency
of sexual problems
• 5-point Likert scale (0 – 4)
• Higher scores indicate greater impairment.
Sexual Satisfaction Scale (SSS) [61, 87] Study-specific items measuring relational sexual
satisfaction for male and female partners
• Higher scores indicate less impairment.
Sexual Satisfaction Scale (SSS) [88] 17-item study-specific scale measuring sexual satis-
faction among Korean women
• 4-point Likert scale (1 – 4); total score 17 – 68
• Higher scores indicate less impairment.
Sexual Self Schema Scale [89] 50- item, trait-adjectives scale measuring women’s
sexual self-perception
• 7-point Likert scale (0 – 6)
• Higher scores indicate better self-perception.
Visual Analog Scale for Vaginal Dryness and
Dyspareunia [29]
Linear rating scale measuring vaginal dryness and
pain
• 10-point scale (0 – 10)
• High scores indicate greater impairment.
Vaginal Atrophy Symptom [29, 90–92] Adapted 3-item scale measuring vaginal dryness,
itching/irritation, dyspareunia
• 4-point Likert scale (0 – 3); total score 0 – 9
• Higher scores indicate greater impairment.
Vaginal Dryness, Vaginal Itching, Dyspareunia
[23, 32]
Study-specific items measuring vaginal dryness,
vaginal itching, and dyspareunia
• 5- or 10-point Likert scale (depending on
study)
• Higher scores indicate greater impairment.
Vaginal Health Index (VHI) [93, 94] 6-parameter gynecological examination rating
appearance of vaginal mucosa
• Score of 1 to 5; total score 6 – 30
• Higher index indicates healthier appearance.
Vaginal Maturation Index (VMI) [91, 95] Gynecological examination determining vaginal
atrophy
• Score of 0 – 100 (%)
• Higher scores indicate less vaginal atrophy.
• A score of < 50 indicates vaginal atrophy.
Vaginal Symptoms Score (VSS) [24, 95] Study-specific scale measuring severity of vaginal
atrophy
• 5-point Likert scale (0 – 4)
• Higher scores indicate more symptoms.
aAll scales were designed as self-report questionnaires (unless otherwise reported as an examination, interview, or visual analog scale)
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clonidine or bupropion and examined if sexual function
differed by these medications [41, 42]. There were no dif-
ferences in sexual function between women treated with
venlafaxine compared to clonidine nor with women
treated with bupropion versus placebo [41, 42].
Physical therapy interventions
Three RCTs tested physical activity interventions on the
primary outcomes of hot flashes, lymphedema, or phys-
ical strength and measured sexual health secondarily
(Tables 5 and 6, Fig 2c). All participants completed pri-
mary breast cancer treatment. There were no studies on
pelvic floor physical therapy. Included studies were con-
ducted in the Netherlands, Sweden and United States. A
home-based, self-directed exercise program intervened
on 422 BCS and did not improve sexual habit, frequency
or discomfort as measured by the Sexual Activity Ques-
tionnaire [43]. In the two arms with cognitive behavioral
therapy, with or without exercise, there was a modest effect
on improving sexual health habit at 24 weeks when com-
pared to waitlist controls. Strength training over one year
in the second trial of 295 participants was associated with
a small improvement in self-perceptions of appearance and
sexuality [44]. Finally, a general physical training and cop-
ing skills intervention in 199 cancer survivors (80 % with
breast cancer) did not directly address sexual health and
did not find change in frequency of sexual problems [45].
Counseling and educational interventions
Seventeen RCTs delivered counseling and/or educa-
tional interventions and measured sexual health out-
comes in a total of 2,494 participants (Tables 5 and 6,
Fig 2d). Participants were studied at various stages of
cancer treatment. Studies were conducted in Australia,
Finland, Greece, Korea, Netherlands, United Kingdom,
and United States. Nine studies targeted sexual health
as the primary outcome [46–54]. There was consider-
able heterogeneity on intervention and outcome mea-
surements. Twelve studies intervened on the individual,
while 5 studies intervened on the couple. The majority
delivered in-person interventions, many with additional
telephone-support [46, 53, 55–58]. Two recent studies
tested web-based interventions [46, 54]. Counseling
strategies varied widely, from problem-solving therapy
to sexual therapy to cognitive behavioral therapy. Most
interventions were delivered by nurses, psychologists,
social workers, or peers.
Several findings were consistent. In studies designed
specifically to intervene on sexual health, improvements
in sexual function were observed in the intervention
group compared to controls [46, 48–51], but effect sizes
were generally modest and of unclear clinical signifi-
cance. For example, a 4-month trial tested behavioral
and non-estrogen replacement pharmacologic interven-
tions on menopausal symptoms in 76 BCS [48]. The
Fig. 1 PRISMA Flow Diagram [21]. Description of articles included throughout the different phases of the systematic review
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Table 3 Summary of studies
Vaginal products interventions
Reference Study design Participantsa Intervention description Intervention frequency Outcome measures
Biglia (2010) [24] Prospective cohort
study
• Sample size = 31 Two groups: 12-week intervention: 1. Vaginal Symptoms Score
• Mean age 54.1 in estrogen groups;
46.1 in polycarbophil-based moisturizer
group
1. Estriol cream 0.25 mg (Angelini®)
or micronized estradiol tablet 12.5 mcg
(Vagifem®)
• Product twice weekly 2. Profile of Female Sexual
Function
3. Vaginal Health Index
2. Polycarbophil-based moisturizer 2.5 g
(Replens®)
Dahir (2014) [27] Prospective cohort
study
• Sample size = 13 One group: 4-week intervention: 1. Sexual function (FSFI)
• Mean age 59.7 1. Vaginal compounded testosterone
300 mcg in 0.5 mL
• Daily for 4 weeks
• Aromatase inhibitor treatment
Donders (2014) [32] Prospective cohort
study
• Sample size = 16 One group: 12-week intervention: 1. Serum estradiol, estrone
• Mean age 57.0, range 52-63 1. Tablet with 0.03 mg estriol and L.
acidophilus (Gynoflor®)
• Daily for 4 weeks, then








Gelfand (1994) [25] Prospective cohort
study
• Sample size = 25 One group: 12-week intervention: 1. Vaginal health index
• Mean age 60.1, range 43-78 1. Polycarbophil-based moisturizer 2.5 g
(Replens®)
• Moisturizer three times weekly 2. Vaginal pH
3. Patient-reported sexual
effects
Juraskova (2013) [26] Prospective cohort
study
• Sample size = 25 One group: 26-week intervention: 1. Dyspareunia
• Mean age = 51, range 37-66 1. Polycarbophil-based moisturizer 2.5 g
(Replens®); Pelvic floor muscle relaxation;
and Organic olive oil
• Moisturizer three times weekly 2. Sexual Activity
Questionnaire• In a sexual relationship • Pelvic floor muscle relaxation twice
daily 3. Sexual satisfaction (FSFI





Kendall (2006) [31] Prospective cohort
study
• Sample size = 6 One group: 12-week intervention: 1. Atrophic vaginitis
symptoms• Mean age = 52, range 51-59 1. Micronized estradiol 25 mcg
(Vagifem®)
• Daily for 2 weeks then twice weekly

















Table 3 Summary of studies (Continued)
Lee (2011) [29] Randomized
controlled trial
• Sample size = 98 Two groups: 12-week intervention: 1. Dryness with pain
• Mean age 45.9, range 34-53 in
intervention group; 45.0, range
37-53 in placebo group
1. pH-balanced lactic acid gel (pH 4.0) • Gel three times weekly 2. Dyspareunia
• Double blind 2. Placebo gel (pH 7.2) 3. Vaginal health index
• Placebo control 4. Vaginal pH




Loprinzi (1997) [23] Randomized
controlled trial
• Sample size = 52 Two groups: 9-week intervention: 1. Product preference
• Age≤ 45 = 22 % 1. Polycarbophil-based moisturizer 2.5 g
(Replens®), then
• First product: daily x 5 days, three
times weekly x 23 days
2. Vaginal dryness
Age 46-55 = 38 % 3. Dyspareunia• Double blind
• Cross-over Age≥ 56 = 40 % Placebo (Hydroxymethylcellulose,
glycerine-delta lactone, hydrogenated
palm oil glyceride, water)
• 1 week washout 4. Itching
• Second product: daily x 5 days, three
times weekly x 23 days
2. Placebo, then Replens®
Pfeiler (2011) [30] Prospective cohort
study
• Sample size = 10 One group: 2-week intervention: 1. Vaginal dryness
• Mean age 65, range 50-77 1. Estriol 0.5 mg vaginal tablet • Daily for 2 weeks 2. Dyspareunia
3. Serum estradiol• Aromatase inhibitor treatment
4. Serum FSH
5. Serum LH
Wills (2012) [33] Cross-sectional
study
• Sample size = 48 Three groups: Ongoing interventions: 1. Serum estradiol
• Mean age 60, range 49-67 in
vaginal estrogen groups; 68, range
53-79 in control group
1. 25 mcg estradiol tablet (Vagifem®) 1. Twice weekly ongoing
2. Vaginal estrogen ring (Estring®) 2. Every 90 days ongoing
3. Control: no vaginal estrogen 3. No vaginal estrogen• Aromatase inhibitor or SERM treatment
Witherby (2011) [28] Prospective cohort
study
• Sample size = 21 Two groups: 4-week intervention: 1. Serum estradiol
• Mean age 57, range 47-66 in 150 mcg
group; 56, range 45-69 in 300 mcg group
1. Vaginal compounded testosterone
150 mcg in 1 g cream





• Aromatase inhibitor treatment 2. Vaginal compounded testosterone
300 mcg in 1 g cream















Table 4 Summary of findings
Vaginal products interventions




Biglia (2010) [24] 1. Vaginal Symptoms Score Baseline to 4-week score
change (SD)
No control group Between group comparisons Very Low • Dropout: 16 %
2. Profile of Female Sexual
Function (PFSF)
• Estrogens improved all outcomes
more than Replens®.
1. 4 weeks: p = 0.66
1. Replens®: - 6.3 (4.3) 12 weeks: p = 0.01
3. Vaginal Health Index (VHI) Estrogens: -5.3 (4.7) 2. 12 weeks:
2. Not reported p = 0.19
• Replens® showed no change in
sexual function at 12 weeks.
3. Replens®: +3.0 (1.6) 3. 4 weeks: p = 0.05
Estrogens: +5.9 (3.0) 12 weeks:
Baseline to 12-week score
change (SD)
p = 0.02
• Serum estradiol increased 1.4-3.1
pg/mL in Estrogens group (p > 0.05).




2. Replens®: +2.1 (9.3)
Replens®
1. 4 weeks: p = 0.01
Estrogens: +7.2 (5.4)
3. Replens®: +2.0 (3.4)
12 weeks: p = 0.72
Estrogens: +8.5 (3.6)
2. 12 weeks: p = 0.70
3. 4 weeks: p = 0.07
12 weeks: p = 0.42
Estrogens
1. 4 weeks: p < 0.01
12 weeks: p < 0.01
2. 12 weeks: p =0.03
3. 4 weeks: p < 0.01
12 weeks: p < 0.01
Dahir (2014) [27] 1. Sexual function (FSFI) Mean (SD) No control Within group comparisons
versus baseline
Low • Dropout: 8 %
1. Pre 8.7 (3.8) • Significant improvement in all FSFI
domains by post-test.Post 18.8 (7.1) 1. p < 0.001
Donders (2014) [32] 1. Serum estradiol, estrone Baseline, 4-week No control Within group comparisons
versus baseline
Low • Dropout: None
2. Serum estriol 1. Only 1 estradiol level
detectable (1.2 pg/mL)
• 1 of 16 participants with detectable
estradiol level (1.2 pg/mL)
at day 28.
3. Vaginal symptoms 1. Descriptive only
2. Peak estriol 104.5 pg/mL,
15.8 pg/mL
2. Descriptive only4. Vaginal pH
3. p < 0.001 for dryness,
soreness3. Improved dryness,
soreness, dyspareunia
5. Vaginal maturation index
4. p < 0.001
6. Serum FSH
4. Mean 6.0, 4.4 5. p < 0.001
7. Serum LH















Table 4 Summary of findings (Continued)
6. Mean 107.9, 98.9 7. p > 0.05
7. Mean 36.5, 34.0
Gelfand (1994) [25] 1. Vaginal health index 1. Mean score (SD) No control Within group comparisons
versus baseline
Low • Dropout: None




1-month 10.8 (0.4) 1. 1-month
3-month 19.7 (0.7) p > 0.05
2. Mean pH (SD) >1 month
Baseline 6.9 (0.2) p <0.001
1-month 6.8 (0.1) 2. 1-month
3-month 4.9 (0.2) p >0.05
3. Pain-free intercourse: >1 month
Baseline 36 % p <0.001








Juraskova (2013) [26] 1. Dyspareunia (Visual
analog score, 0-10)
Mean (SD) No control Within group comparisons
versus baseline
Very Low • Dropout: 36 %
1. Baseline 7.0 (2.4) • Maximum gain in sexual satisfaction




4-week 4.4 (2.4) 1. p < 0.001
26-week 2.7 (2.3) 2. p < 0.001
3. Sexual satisfaction FSFI
subscale (0.8-6) 2. Baseline 7.2 (3.2) 3. p < 0.001
4-week 12.3 (4.3) 4. p = 0.014. Endocrine symptoms
(FACT-ES, 0-72)
26-week 11.6 (4.3) 5. Descriptive only
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Replens® 88 %
Olive oil 76 %
Kendall (2006) [31] 1. Atrophic vaginitis
symptoms (yes/no)
1. 5 of 6 improved No control Descriptive data – no
comparisons
Low • Dropout: None
2. Serum estradiol, pmol/L
2. 5 of 6 had estradiol
levels > 3 pmol/L
3. Serum FSH, IU/l 3. No significant change
4. Serum LH, IU/l 4. No significant change




Baseline, 12-week mean scores
(SD)
Between group comparisons Moderate • Dropout: 12 %
1. p = 0.001 • All outcomes favor intervention.
2. Dyspareunia (Visual
analog score 0-10)
1. 8.2 (0.8), 1. 7.9 (0.9),
2. p = 0.04
4.2 (1.4) 6.5 (1.5)
3. p = 0.002
• Vaginal irritation in 50 %
participants in first 4 weeks.
3. Vaginal health index 2. 8.2 (1.0), 2. 8.1 (1.0),
4. p < 0.0014. Vaginal pH 5.5 (1.1) 6.1 (1.4)
5. p < 0.0015. Vaginal maturation index 3. 15.8 (3.7), 21.0 (3.9) 3. 14.3 (3.7), 17.0 (3.9)
4. 6.5 (1.1), 4. 6.2 (1.1),
5.0 (0.8) 5.7 (0.9)
5. 45.5 (3.5), 51.2 (3.8) 5. 46.4 (3.7), 47.9 (2.7)
Loprinzi (1997) [23] 1. Product preference 1. 41 % prefer Replens® %
score decrease after 4 weeks
treatment:
1. 24 % prefer Placebo %
score decrease after 4 weeks
treatment:
Between group comparisons Moderate • Dropout: 27 %
2. Vaginal dryness (scale 0-4) 1. p = 0.68 • Both groups with improved vaginal
dryness by 1 week.
2. p = 0.33. Dyspareunia (scale 0-4) 2. 64 % 2. 62 %
3. p = 0.054. Itching (scale 0-4) 3. 60 % 3. 41 %
4. Not reported
• Vaginal side effects in 42 %
participants.
4. Not reported 4. Not reported
Pfeiler (2011) [30] 1. Vaginal dryness (yes/no) 1. 5/6 reported
improvement
No control Within group comparisons
versus baseline
Low • Dropout: None
2. Dyspareunia (yes/no)
2. 3/5 reported
improvement3. Serum estradiol, pg/mL
3. All estradiol < 10 pg/mL
after treatment
1. Descriptive only
4. Serum FSH, mU/mL 2. Descriptive only
5. Serum LH, mU/mL
Mean level pre-, post-
3. Descriptive only
4. 4. 75.7, 66.0
4. p = 0.01
5. 5. 32.4, 28.9
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Wills (2012) [33] 1. Serum estradiol 1. Median level (95 % CI)
pre-, post-




Low • Dropout: None
• Systemic absorption occurs with
intravaginal estrogen therapy (ring
or tablet).
- Vaginal tablet 2.9 pmol/L
(2.9-4.9), 45 pmol/L (19-89)
1. Versus vaginal tablet p = 0.93,
p < 0.001;
- Vaginal ring 15.0 pmol/L
(2.9-19), 15 pmol/L (1.9-35) Versus vaginal ring
p < 0.014, p < 0.014
Witherby (2011) [28] 1. Serum estradiol 1. % < 5 pg/mL No control 1. p = 0.91 Low • Dropout: 10 %
2. Vaginal atrophy symptom
(Likert scale, 0-12)
Baseline 100 % 2. p < 0.001
• Two estradiol levels elevated after
testosterone (both <8 pg/mL).
4-week 90 % 3. p = 0.03
3. Vaginal pH
2. Mean (SD) 4. p < 0.001
4. Vaginal maturation index
(VMI) Baseline 5.9 (1.9)
• Adverse effects: hair growth/acne
(n = 3), vaginal irritation (n = 3)
























Fig. 2 Risk of Bias Summary. Risk of bias figures detailing the review authors’ judgements about each risk of bias item for each included study organized
by type of intervention: a Vaginal products interventions, b Systemic therapy interventions, c Physical activity interventions, d Counseling and
educational interventions
Seav et al. Women's Midlife Health  (2015) 1:9 Page 13 of 27
Table 5 Summary of studies
Systemic therapy interventions
Reference Objective Participantsa Intervention description Intervention frequency Outcome measures
Barton (2007) [34] To test transdermal testosterone for
increasing sexual desire
• Sample size = 150 Two groups: 8-week intervention: 1. Sexual desire (CSFQ desire
subscale)• Mean age 52.3 (SD 7.9) 1. Vanicream + 2 % testosterone (T),
then Vanicream (placebo)
• First product: daily x 4
weeks 2. Pleasure (CSFQ pleasure
subscale)
• Post-menopause status
• Second product: daily x 4
weeks 3. Sexual function (CSFQ
total score)
• History of any cancer
(73 % breast cancer)
2. Vanicream (placebo), then Vanicream +







• Testosterone dose 10.4 mg daily
6. Serum SHBG
7. Serum AST
Buijs (2009) [42] To test venlafaxine versus clonidine
on hot flashes
• Sample size = 60 Two groups: 18-week intervention: 1. Sexual function (Sexual
Activity Questionnaire)• Median age 49-51,
range 35-60
1. Clonidine (C) then Venlafaxine (V) • One medication daily x 8
weeks
• History of breast
cancer
2. Venlafaxine, then Clonidine or vice
versa • 2-week washout
•≥ 14 hot flashes/week
• Second medication daily x
8 weeks
• V: 75 mg once daily
• C: 0.05 mg twice daily
Nunez (2013) [41] To test bupropion on hot flashes • Sample size = 55 Two groups: 10-week intervention: 1. Sexual function (Arizona
Sexual Experience Scale)• Median age 49, range
33-71
1. Bupropion (B), then placebo • One medication daily x 3
days, then twice daily for 25
days• History of breast
cancer
2. Placebo then bupropion
•≥ 7 hot flashes/week
• B: titrated to 300 mg daily
• 1-week washout
• Second medication daily x
3 days, then twice daily for
25 days
Physical Activity Interventions
Berglund (1994) [45] To test physical training, information
and coping skills training on physical
strength, information need and
mood symptoms
• Sample size = 199 Two groups: 7-week intervention, 3-
months follow up:
1. Sexual problems
frequency• All cancers (80 %
breast cancer)
1. Structured rehabilitation run by oncology
nurse: 1. Twice-weekly 2-h sessions
for first 4 weeks, then one-
weekly 2-h session for 3
weeks
• Within 2 months of
completing primary
cancer treatment
Group sessions on physical training, cancer
information, coping training
2. 0 or 1 information session
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Duijts (2012) [43] To test cognitive behavioral therapy
and physical exercise on
menopausal symptoms
• Sample size = 422 Four groups: 12-week intervention: 1. Sexual function (Sexual
Activity Questionnaire, habit
subscale)
• Mean age 48.2 (SD 5.6) 1. Cognitive behavioral therapy (CBT): Group
sessions on reducing menopausal symptoms
1. 6 weekly groups and 12th
week refresher• ≥ 2 menopausal
symptoms over prior 2
weeks
2. Physiotherapist follow up
in weeks 4 and 8
2. Physical exercise (PE): Home-based,
self-directed exercise program to achieve




Speck (2010) [44] To test strength training on
perceptions of body image
• Sample size = 295 Two groups: 1-year intervention: 1. Self-perception of appear-




• Mean Age 56.5 (SD 9) 1. Weight-lifting group instruction at
community fitness center on warm-up, core
exercises, weight-lifting exercises
1. First 13 weeks: twice
weekly group sessions
• Lymphedema or at risk
for lymphedema Remaining of year: twice
weekly unsupervised
exercise; Fitness trainers
called participants if they
missed sessions.
2. Waitlist control
2. Maintain usual exercise
level
Individual-based Counseling and Educational Interventions
Allen (2002) [55] To test problem-solving therapy for
problems and emotional difficulties
• Sample size = 164 Two groups: 16-week intervention: 1. Sexual health (CARES
sexual subscale)• Mean age 42.3 (SD 5.4) 1. Problem-solving therapy: Training sessions
and manual on problem solving targeting
mid-life breast cancer patients
1. 6 biweekly training
sessions with nurse: 2 in




2. Controls: No therapy
Anderson (2015) [46] To test a behavioral intervention on
menopausal symptoms
• Sample size = 55 Two groups: 12-week intervention: 1. Sexual function (sexual
function subscale, Greene
Climacteric Scale)
• Mean age 49.2 (SD 6.2) 1. Multi-modal tailored program: 1. Nurse consultation at
weeks 1, 6, 12• < 12 months from
primary cancer
treatment
Goal setting in consultation with nurse,
follow up calls and emails, written health




2. Controls: Booklet on breast cancer and
early menopause
Ganz (2000) [48] To test behavioral and non-estrogen
replacement pharmaco-logic inter-
ventions on menopausal symptoms
• Sample size = 76 Two groups: 4-month intervention: 1. Menopausal Symptom
Scale Score (hot flash,
vaginal and urinary
subscales of BCPT Symptom
Checklist)
• Mean age 54.5 (SD 5.9) 1. Intervention: 1. Months 0, 2 and 4 visits
2. Sexual health (sexual
summary subscale of CARES)
• > 1 menopausal
symptom as moderate
or severe
Individualized plans of education, counseling,
pharmacologic and/or behavioral
interventions, psychosocial support, referrals
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Germino (2013) [56] To test an uncertainty management
intervention in young survivors
• Sample size = 313 Two groups: 10-month intervention: 1. Sexual function (Medical
Outcomes Study – Sexual
Functioning)• Mean age 44
1. Uncertainty management strategies: CD
on cognitive and behavioral strategies,
written guide booklet on long-term
treatment effects, breast cancer resource
guide, calls by nurse
1. Weekly 20-min calls x 4
2. Weekly 20-min calls x 4
2. Attention control: Calls by psychology
graduate students to talk about cancer
experience but no advice offered
Greer (1992) [59] To test psychological therapy on
quality of life




Adjustment to Illness Scale)
• Mean age 51 (SD13.6) in
therapy group; 52 (SD11.7)
in the control group
1. Psychological therapy: Cognitive
behavioral therapy for coping with cancer 1. Weekly sessions x 8
• All cancers except
central nervous system
and non-melanoma skin
cancer (52 % breast
cancer)
2. Controls: No therapy
• Psychological
morbidity
Jun (2011) [49] To test a sexual life reframing
program on marital intimacy, body
image, and sexual function
• Sample size = 60 Two groups: 6-week intervention: 1. Marital intimacy (Martial
Intimacy Questionnaire)• Mean age 45.7 (SD 6.4)
in intervention group;
46.2 (SD 6.9) in control
group
1. Sexual reframing program: Group sessions
of up to 10 women; Sessions on relaxation,
perception of problem, exposure, solving
problems, acceptance, reframing
1. Weekly 2 h sessions x 6
2. Sexual interest (subscale,
CARES)
3. Sexual dysfunction
(subscale, CARES)• Married with male
partner 4. Sexual satisfaction (Sexual
Satisfaction Scale)
2. Usual care: Offered intervention for 2 h
after final data collection
Marcus (2010) [57] To test a telephone counseling
program on psychosocial outcomes




body image subscales of
Sexual Dysfunction Scale)
• Age < 50: 49 % 1. Telephone Counseling: Booklet with
community breast cancer resources;
telephone sessions with counselors;
Wellness Kit with 6 thematic booklets,
2 progressive relaxation tapes, stress
management guide; cognition- and
emotion-focused worksheets
• Recent primary cancer
treatment completion
1. 45-min telephone ses-
sions: biweekly x 10, then
monthly x 6
2. Control: Booklet with community breast
cancer resources
Rowland (2009) [51] To test a psycho-educational group
intervention on sexuality and
intimacy
• Sample size = 411 Two groups: 6-week intervention: Likert scales:
• Mean age 57, range 35-86 1. Intervention: Group therapy led by social
workers on education, communication
training, sensate sex therapy
1. Weekly group sessions x 6 1. Satisfaction with variety of




3. Dyspareunia2. Control: Educational pamphlet on cancer
survivorship 4. Pain interferes with pleasure
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Salonen (2009) [58] To test a telephone-based social
support intervention on quality of
life
• Sample size = 250 Two groups: 1-time intervention, 2-week
follow-up:
1. Sexual functioning
(subscale, EORTC QLQ-BR23)• Mean age 56-57, range
24-75
1. Telephone support by physiotherapist:
education about illness, at-home exercises,
counseling on stress-related problems,
exploring patient demands and exercises
1. 1-week after breast sur-
gery phone call with therap-
ist (length 3-25 min)
• Newly diagnosed with
breast cancer
2. Control: No telephone support
Schover (2006) [52] To test peer counseling on
improving sexual function,
knowledge about reproductive
health, menopausal symptoms and
infertility-related distress
• Sample size = 60 Two groups: Immediate counseling
intervention, 3-month follow
up:
1. Sexual Dysfunction (FSFI)
• Mean age 49.2, range
30-77
1. Intervention: In-person peer counselor
sessions reviewing Sisters Peer Intervention
in Reproductive Issues after Treatment
(SPIRIT)
1. 60-90 min peer counsel-
ing sessions x 3
• African American
2. Control: Waitlist control with SPIRIT and
peer counseling at the end of study
Schover (2011) [53] To test peer counseling on
improving sexual function,
knowledge about reproductive
health, menopausal symptoms and
infertility-related distress
• Sample size = 300 Two groups: 6-week intervention, 6-
month, 12-month follow up:
1. Sexual Dysfunction (FSFI)
• Mean age 54.4 (SD 9.7)
for peer group; 54.0 (SD
9.8) for telephone
group
1. Intervention: In-person peer counselor
sessions reviewing Sisters Peer Intervention
in Reproductive Issues after Treatment
(SPIRIT)
1. 60-90 min peer counsel-
ing sessions x 3
• African American 2. 30 min call to counselor
encouraged x 1
2. Control: Telephone counseling and SPIRIT
workbook
Vos (2004) [60] To test a group intervention (group
psycho-therapy or social support) on
psychosocial adjustment
• Sample size = 87 Three groups: 12-week intervention, 3-
month follow up:
1. Sexual function (subscale,
EORTC QLQ-BR32)• Mean age 49.2, range
29-68
1. Psychotherapy: Group therapy with
cognitive behavior components 1. Weekly 2.5 h sessions x
12; post-treatment 1 and 2
month 2.5 h sessions
• Newly diagnosed with
breast cancer
2. Social support: Group therapy with peer
support
2. Weekly 2.5 h sessions x
12; post-treatment 1 and 2
month 2.5 h sessions
3. Waitlist control
1 & 2 Group interventions discussed fear of
recurrence, coping, body image, sexuality,
intimacy, social support.
Couples-based Counseling and Educational Interventions
Baucom (2009) [47] To test couple-based relationship
enhancement on relational distress
• Sample size = 14 Two groups: 12-week intervention, 12-
month follow up:
1. Marriage quality (Quality
of Marriage Index)• Median age 50, range
30-80
1. Relationship enhancement intervention:
Cognitive behavioral therapy on
cancer-related topics• Married with male
partner
1. Biweekly 75 min sessions
with therapist x 6
2. Sexual function (Derogatis
Inventory of Sexual
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Christensen (1983)
[61]
To test a structured couples
treatment program on psychosocial
discomfort
• Sample size = 20 Two groups: 6-week intervention: 1. Sexual satisfaction (Sexual
Satisfaction Scale)• Mean age 39.7 1. Therapy sessions on communication and
problem solving
1. Weekly sessions x 4
• Married with male
partner
• Recent mastectomy
2. Controls: No therapy
Kalaitzi (2007) [50] To test combined couples and
sexual therapies on sexual and body
image problems
• Sample size = 40 Two groups: 12-week intervention: 1. Sexual desire frequency
• Mean age 51.8 for
intervention group, 53.3
for control group
1. Intervention: Therapy sessions - 1st in hospital;
communication training, sensate focus, body
imagery, therapist separation
1. Biweekly sessions x 6 2. Intercourse frequency
3. Masturbation frequency
• Married and sexually
active with male partner
4. Orgasm frequency
5. Initiative for sex
• Recent simple
mastectomy
2. Control: no therapy
6. Satisfaction with
relationship
Schover (2013) [54] To test an Internet-based interven-
tion, with and without sexual coun-
seling, on sexual function and
satisfaction
• Sample size = 72 Two groups: 12-week intervention, 6-
month follow up:
1. Sexual function (FSFI)
• Mean age 53 (SD 9) 1. Intervention: In-person counseling to review




• History of breast





(FSFI score < 26.5)
Both groups: Website on sexual and fertility
consequences of cancer, genital anatomy,
management of vaginal dryness, communication,
dating, treatments for loss of desire, resuming sex
comfortably.
• In a partnered
relationship
Scott (2004) [96] To test a couples-based intervention
on adjustment to cancer
• Sample size = 94 Three groups: 6-month intervention, 12-
month follow up:
1. Sexual self schema (Sexual
Self Schema Scale)• Mean age 51 (SD 9.8) 1. Couple coping training: Booklet, in-person cou-
ples counseling on coping and support• Newly diagnosed
breast (61 %) or
gynecologic cancer
1. 2-h counseling sessions at
baseline, 1-week, 5-weeks, 6
months; telephone calls at 1
and 3 months
2. Sexual desire (subscale,
Brief Index of Sexual
Function)
• In a partnered
relationship
2. Medical information education: Booklet on
cancer and brief telephone calls
3. Sexual arousal (subscale,
Brief Index of Sexual
Function)
2. Telephone calls (<15 min)
at baseline, 1- and 2-week
post-surgery, 6 and 9
months
3. Patient coping training: Booklet and in-person
counseling, telephone calls on coping and
support
3. 2-h counseling sessions at
baseline, post-surgery, 1-
week, 6 months; telephone
calls at 1 and 3 months
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Systemic Therapy Interventions




Barton (2007) [34] All measures normalized to 100 point
scale:
Mean change (95 % CI): Mean change (95 % CI): 1. p = 0.58 Moderate • Dropout: 12 %
1. 5.5 (2.2-8.8) 1. 4.4 (2.4-6.5) 2. p = 0.11 • Side effects and
quality of life did
not differ by group.
1. Sexual desire (CSFQ desire subscale)
2. 9.4 (7.0-11.2) 2. 4.7 (0.4-9.0) 3. p = 0.14
2. Pleasure (CSFQ pleasure subscale)
3. 5.7 (4.1-10.6) 3. 3.4 (2.1-6.8) 4. p < 0.001 for
both measures3. Sexual function (CSFQ total score) 4. Total 92.8 (74.9-110.7) 4. Total 1.2 (-1.8-4.3)
5. p = 0.824. Serum testosterone, ng/dL Free 1.6 Free 0.18 (-0.1-0.5)
6. p = 0.115. Serum estradiol, pg/mL (1.2-2.0) 5. 0.5 (-5.2-6.1)
7. p = 0.936. Serum SHBG, nmol/L 5. -0.3 (-2.9-2.4) 6. -0.3 (-3.0-2.3)
7. Serum AST, U/L 6. -3.1 (-5.1- -1.0) 7. 0.2 (-1.1-1.5)
7. -0.23 (-1.3-0.8)
Buijs (2009) [42] 1. Sexual function (Sexual Activity
Questionnaire)
1. Venlafaxine: No change 1. No control 1. Not reported Moderate • Dropout: 33 %
Clonidine: No change
Nunez (2013) [41] 1. Sexual function (Arizona Sexual
Experience Scale)
Pre- to post- difference (SD): Pre- to post- difference (SD): 1. p = 0.5 Moderate • Dropout: 11 %
1. 1.4 (3.8) 1. 0.6 (3.4)
Physical activity interventions
Berglund (1994) [45] 1. Sexual problems frequency (Scale 0-4) Pre, post, 3-month mean scores (SD): Pre, post, 3-month mean scores (SD): 1. Not
significant
High • Dropout: 8 %
1. 0.7 (1.2), 0.6 (1.0), 0.5 (1.0) 1. 0.6 (1.0), 0.5 (0.9), 0.4 (0.7)
Duijts (2012) [43] 1. Sexual function (Sexual Activity
Questionnaire, habit subscale)




Moderate • Dropout: 17 %
• Significant under-
compliance:
1. CBT: 0.3 (0.8), 0.5 (0.8) 1. 0.6 (0.8), 0.6 (0.8)
1. CBT: 0.31, p
= 0.13
PE: 0.6 (0.8), 0.6 (0.8)
PE: 0.01,
58 % CBT; 64 % PE;





Speck (2010) [44] 1. Self-perception of appearance and
sexuality (Body Image Relationships Scale
appearance and sexuality subscale)
Mean % change (SD): Mean % change (SD): 1. p = 0.004 Moderate • Dropout: 21 %
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Individual-based counseling and educational interventions
Allen (2002) [55] 1. Sexual health (CARES sexual subscale) Baseline, 4-month mean scores (SD): Baseline, 4-month mean scores (SD): 1. p > 0.05 High • Dropout: 9 %
2. p > 0.052. Marital relationship (CARES marital
subscale)
1. 2.2 (1.1), 2.1 (0.9) 1. 2.0 (1.0), 2.0 (0.9)
2. 1.8 (0.8), 1.7 (0.7) 2. 1.6 (0.7), 1.5 (0.6)
Anderson (2015) [46] 1. Sexual function (sexual function
subscale, Greene Climacteric Scale)
Baseline, 12-week mean score (SD) and
effect size Cohen’s d:
Baseline, 12-week mean score (SD) and
effect size Cohen’s d:





1. 2.0 (1.0), 1.3 (1.0) 3. 1.6 (1.1), 1.4 (1.0)
d = 0.65 d = 0.18
Ganz (2000) [48] 1. Menopausal Symptom Scale Score
(hot flash, vaginal and urinary subscales
of BCPT Symptom Checklist)
Mean change score (95 % CI): Mean change 1. p < 0.01 Moderate • Dropout: 5 %
1. 0.57 score (95 % CI): 2. p = 0.03 • Both groups used
educational
materials.(0.40-0.74) 1. 0.092. Sexual health (sexual summary








Germino (2013) [56] 1. Sexual function (Medical Outcomes
Study – Sexual Functioning)
Mean score (SD) at baseline, 4-6
months, 8-10 months:
Mean score (SD) at baseline, 4-6
months, 8-10 months:
1. p = 0.03 at 4-
6 months fol-
low up
Moderate • Dropout: None





1. 2.1 (1.0), 2.0 (1.0), 2.0 (1.1) 1. 2.3 (1.1), 2.3 (1.1), 2.2 (1.1)
Greer (1992) 1. Sexual relationships (subscale of
Psychological Adjustment to Illness Scale)
Mean difference (SD) from baseline to
8-weeks, to 4-months:
Mean difference (SD) from baseline to
8-weeks, to 4- months:
1. p = 0.53 at 8-
week, p = 0.47
at 4-months
Moderate • Dropout: 21 %
1. 0.7 (7.2), -1.3 (7.7) 1. -0.4 (8.1), -1.4 (8.2)
Jun (2011) [49] 1. Marital intimacy (Martial Intimacy
Questionnaire)
Change in mean (SD) scores: Change in mean (SD) scores: 1. p = 0.29 Low • Dropout: 25 %
1. +2.0 (5.0) 1. +0.6 (2.1) 2. p = 0.45
2. Sexual interest (subscale, CARES)
2. -0.2 (0.6) 2. -0.1 (0.9) 3. p = 0.53
3. Sexual dysfunction (subscale, CARES)
3. -0.1 (1.0) 3. +0.1 (1.1) 4. p < 0.001
4. Sexual satisfaction (Sexual Satisfaction
Scale) 4. +5.3 (9.0) 4. -3.4 (5.8)
Marcus (2010) [57] 1. Sexual function, (behavioral, evaluative
and body image subscales of Sexual
Dysfunction Scale)
Baseline, 12- and 18-month mean scores
(approximated from figure):





Moderate • Dropout: 20 %
1. 47, 40, 40 1. 45, 43, 43
1. p = 0.03 at
12-month,
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• Dropout: 56 %
1. Satisfaction with variety of sexual
activities 1. 0.1 (1.2) 1. -0.03 (1.0) 1. p = 0.23
• Intervention
group: 89/284
(29 %) agreed to
participate; 72/284
(25 %) attended≥ 1
session.
2. 0 (1.5) 2. -0.3 (1.0) 2. p = 0.022. Relationship satisfaction
3. 0.7 (1.5) 3. -0.1 (1.7) 3. p = 0.093. Dyspareunia
4. 0.3 (1.4) 4. 0 (1.1) 4. p = 0.294. Pain interferes with pleasure
5. Not reported 5. Not reported 5. p = 0.035. Improved comfort with sexuality
Salonen (2009) [58] 1. Sexual functioning (subscale 0-100,
EORTC QLQ-BR23)
Mean score (SD): Mean score (SD): 1. p = 0.2 High • Dropout: 9 %
1. 29 (26) 1. 24 (22)
Schover (2006) [52] 1. Sexual Dysfunction (FSFI) 1. Not reported 1. Not reported 1. No difference Very low • Dropout: 20 %
Schover (2011) [53] 1. Sexual Dysfunction (FSFI) 1. Not reported 1. Not reported 1. No difference Very low • Dropout: 38 %






Low • Dropout: 21 %
Couple-based counseling and educational interventions
Baucom (2009) [47] 1. Marriage quality (Quality of Marriage
Index)
Baseline, 12-week, 12-month mean
score (SD):





Low • Dropout: 14 %
2. Sexual function (Derogatis Inventory
of Sexual Functioning)
1. Female: 34.0 (13.6), 39.3 (4.7), 39.7
(3.5)
1. Female: 40.8 (6.0), 42.2 (4.1), 40.2 (5.1) Baseline to 12-
weeks
Male: 39.3 (6.6), 39.6 (5.9), 39.6 (5.2) Male: 42.5 (3.0), 37.5 (13.6), 41.0 (6.2)
1. Female 0.48
Male 0.642. Female: 11.5 (5.0), 12.7 (4.1), 13.0 (3.1) 2. Female: 10.3 (4.8), 9.8 (5.8), 9.8 (5.9)
2. Female 0.34
Male 0.38







Christensen (1983) [61] 1. Sexual satisfaction (Sexual Satisfaction
Scale)
Post-test mean score (SD): Post-test mean score (SD): 1. p < 0.05 for
both partners
High • Dropout: None















Table 6 Summary of findings (Continued)
Male partner: 81.3 (28.7) Male partner: 67.3 (28.6)
Kalaitzi (2007) [50] 1. Sexual desire frequency Baseline, 12-week mean scores (95 %
CI):
Baseline, 12-week mean scores (95 %
CI):
1. p = 0.73 • Dropout: None
2. Intercourse frequency 2. p = 0.14
3. Masturbation frequency
1. 2.9 (2.3-3.4), 2.8 (2.3-3.2) 1. 3.0 (2.6-3.4), 2.7 (2.2-3.1)
3. p = 0.32
4. Orgasm frequency
2. 3.2 (2.7-3.6), 2.9 (2.5-3.3) 2. 3.2 (3.0-3.4), 2.5 (2.1-2.9)
4. p = 0.03
5. Initiative for sex
3. 1.9 (1.4-2.3), 1.6 (1.2-2.0) 3. 1.9 (1.6-2.2), 1.9 (1.5-2.2)
5. p < 0.001
6. Satisfaction with relationship
4. 3.3 (2.8-3.8), 3.7 (3.4-4.0) 4. 3.6 (3.1-4.0), 3.1 (2.6-3.6)
6. p = 0.01
5. 2.2 (1.8-2.6), 2.7 (2.3-3.0) 5. 2.6 (2.2-3.0), 1.8 (1.4-2.2)
6. 3.8 (3.3-4.2), 4.5 (4.2-4.7) 6. 3.3 (2.9-3.7), 3.7 (3.2-4.1)
Schover (2013) [54] 1. Sexual function (FSFI) Linear mixed model coefficients, post-
treatment versus baseline:
Linear mixed model coefficients, post-
treatment versus baseline:
1. p = 0.024 Low • Dropout: 36 %
2. Sexual satisfaction (Menopausal Sexual
Interest Questionnaire)
2. p = 0.01
1. 7.4 1. 2.8
2. 13.2 2. 3.4
Scott (2004) [96] 1. Sexual Self Schema Scale Baseline, post-treatment mean
score(SD):






Moderate • Dropout: 11 %
2. Sexual desire (subscale, Brief Index of
Sexual Function) Couples coping Medical information
1. d = 0.8,
p < 0.05
3. Sexual arousal (subscale, Brief Index of
Sexual Function)
1. 57.3 (13.5), 62.8 (12.2) 1. 55.4 (14.3), 55.8 (11.0)
2. No difference
2. 4.2 (2.8), 4.0 (2.3) 2. 3.1 (1.9), 2.4 (2.4)
3. No difference
3. 2.7 (2.5), 2.0 (2.0) 3. 1.9 (1.4), 1.6 (1.6)
Patient coping
1. 55.7 (14.3), 56.0 (12.0)
2. 3.7 (2.6), 2.7 (2.9)















intervention group received individualized plans of edu-
cation, counseling, pharmacologic and/or behavioral
interventions, psychosocial support, and referrals com-
pared to controls who underwent usual care. Sexual
function was measured by the CARES Sexual Summary
Scale, which is scored from 0 to 4 (higher score indicat-
ing more severe problems). The mean score change of
the intervention group (0.46, 95 % CI 0.30–0.62) was
statistically significantly larger than that of the control
group (0.11, 95 % CI −0.16 to 0.38), p = 0.03, but clinical
relevance is unclear. Most studies intervening on general
psychosocial health, rather than targeting sexual health,
did not appear to improve sexual function [55, 58–60].
Researchers who undertook group therapy interventions
reported difficulties with attendance and higher dropout
rates [49, 51]. Couple-based therapy incorporated coun-
seling on cancer, sexual health, and communication and
consistently improved various aspects of sexual function,
most frequently sexual satisfaction [47, 50, 61].
Discussion
The majority of BCS experience sexual problems in sur-
vivorship, most commonly vaginal and vulvar dryness.
Despite the significant population of BCS and high
prevalence of sexual problems, the number of RCTs
intervening on sexual health was limited. This review
summarized evidence for BCS across all ages, because
trials in midlife BCS were few. Results showed signifi-
cant evidence for regular use of vaginal moisturizers to
improve dryness, dyspareunia, and sexual satisfaction.
Uncontrolled studies with vaginal estradiol, estriol or
testosterone also improved vaginal symptoms, but
showed systemic absorption. Educational and counseling
interventions, particularly those targeting sexual dys-
function, improved various aspects of sexual health. No
consistent improvements in sexual health were observed
with physical activity, transdermal testosterone or hot
flash interventions. Overall for most included studies,
the quality of evidence by GRADE criteria was moderate
to low.
Vulvovaginal symptoms occur in 20 to 50 % of healthy
women of midlife and older as a result of estrogen
deprivation [62]. BCS are at heightened risk of these
symptoms because chemotherapy, oophorectomy and/or
endocrine therapies further decrease estrogen exposure.
The clinical trial data show improvements in vaginal
dryness, dyspareunia, sexual satisfaction and frequency,
and vaginal pH with regular use at least 2-3 times
weekly of a polycarbophil-based vaginal moisturizer.
Compliance for at least twelve weeks is important,
because major symptom gains occurred between 1-3
months and recur after stopping use, similar to data in
the general population [63]. Vulvovaginal symptom relief
from regular use of other moisturizers is likely, and pH
balance in products may be important [23, 29]. Among
available vaginal moisturizers, BCS should consider pref-
erentially using products with evidence of efficacy.
Use of minimally absorbed local vaginal estrogens and
androgens provide vaginal symptom relief, with local
estrogens appearing more effective than non-hormonal
moisturizers [24, 64]. Even at low doses, estradiol tablets
and creams and compounded testosterone are systemic-
ally absorbed [24, 28, 30–33]. Unfortunately, there are
no clinical trial data on adverse breast cancer outcomes
with extended use. Nor are there studies in BCS that
compare 7, 10 and 25 micrograms of vaginal estradiol
for symptom control and systemic absorption. Whether
risk of breast cancer recurrence or death would be
higher in estrogen-responsive tumors is also unknown.
As local estrogens and androgens are not FDA-approved
for use in BCS, these medications are prescribed off-
label and use requires careful discussion between BCS
and their healthcare providers.
There was a lack of evidence to support incorporating
systemic interventions or physical therapy into the treat-
ment paradigm for sexual dysfunction. The single trial
on transdermal testosterone did not demonstrate greater
sexual desire compared to the placebo cream after 1
month of use [34]. These findings stand in contrast to
several trials in women without prior breast cancer in
which androgen therapy improved sexual desire, poten-
tially because these trials were longer in duration (12-24
weeks) and provided supplemental estrogen [35–40].
Notably, there were no clinical trials on treating sexual
dysfunction related to serotonin receptor uptake inhibi-
tors in BCS.
Multiple counseling and educational strategies, par-
ticularly those targeting sexual dysfunction, have been
shown to improve sexual health in BCS. Marriage and
family therapists, sex therapists, sexual counselors or
psychologists offer counseling interventions. With the
aid of online resources, BCS can look for providers who
are appropriately educated, credentialed or have signifi-
cant prior experience with sexual health after cancer.
Excellent online resources are found on sites for the
American Association of Sexuality Educators, Coun-
selors, and Therapists, the International Society for the
Study of Women’s Sexual Health, and the American
Cancer Society. A number of investigators have designed
educational interventions using printed materials, CDs,
and websites for content with healthcare provider or
peer support [46, 48, 52–54]. This approach is important
to study further, as it has the potential advantage of be-
ing delivered remotely to extend access to BCS who do
not have specialized care locally.
The strength of this review is the systematic approach
to identifying and grading current evidence on sexual
health interventions specific to breast cancer survivors.
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This approach enabled us to identify the gaps in data.
Several interventions that have shown promise in
women without a history of breast cancer have not
undergone clinical trials in BCS. These include ospemi-
fene and systemic DHEA for the treatment of vulvovagi-
nal symptoms and flibanserin for the treatment of
arousal and sexual interest disorders [65, 66]. The pri-
mary limitation was heterogeneity of interventions and
outcome measures that restricted the ability to pool data
from studies of limited sample size. A recent systematic
review sought to evaluate the psychometric properties of
sexual dysfunction screening tools and the extent to
which they measure DSM-5 aspects of sexual dysfunc-
tion for BCS [67]. The review found 31 different scales
measuring sexual function, of which the Arizona Sexual
Experience Scale, Female Sexual Function Index, and
Sexual Problems Scale were determined to meet criteria
for acceptable psychometric properties while incorporat-
ing DSM-5 areas of sexual dysfunction. Future studies in
BCS should carefully consider these outcome measures
in study design.
This review demonstrated that current evidence on in-
terventions for improving sexual interest, orgasm and
genitopelvic pain in BCS of midlife is limited in quantity
and moderate to low in quality. From these data, we rec-
ommend prolonged and regular use of non-hormonal
vaginal moisturizers to alleviate vulvar and vaginal dry-
ness symptoms and dyspareunia. We also recommend
seeking educational and counseling interventions. A
number of online resources on sexual health after breast
cancer may be useful for BCS and their providers
(Table 7). Because each of these interventions have lim-
ited efficacy, clinical trials to test novel interventions




(("Clinical Trial"[Publication Type] OR "Comparative
Study"[Publication Type]) OR ("Phase I Clinical Trial"
OR "Phase II Clinical Trial" OR "Phase III Clinical Trial"
OR "Phase IV Clinical Trial" OR "Controlled Clinical
Trial" OR "Multicenter Study" OR "Observational Study"
OR "Randomized Controlled Trial" OR "Pragmatic Clinical
Trial" OR "Comparative Study")).
AND (("Breast Neoplasms"[Mesh] NOT "Breast Neo-
plasms, Male"[Mesh]) OR ("Breast cancer" OR "Breast
Neoplasms")).
AND (("Sexual Dysfunctions, Psychological/prevention
and control"[Mesh] OR "Sexual Dysfunctions, Psycho-
logical/rehabilitation"[Mesh] OR "Sexual Dysfunctions,
Psychological/therapy"[Mesh] OR "Sexual Dysfunction,
Physiological/prevention and control"[Mesh] OR "Sexual
Dysfunction, Physiological/rehabilitation"[Mesh] OR "Sexual
Dysfunction, Physiological/therapy"[Mesh] OR "Vaginal
Creams, Foams, and Jellies"[Mesh] OR "Biofeedback,
Psychology"[Mesh] OR "Cognitive Therapy"[Mesh] OR
"Psychotherapy"[Mesh] OR "Sex Counseling"[Mesh]
OR "Patient Education as Topic"[Mesh] OR "Testosterone/
therapy"[Mesh] OR "Antidepressive Agents"[Mesh]) OR
Table 7 Patient Resources: Companion document for use by women seeking management for female sexual dysfunction
What type of information is here? What organization provides this resource? Link to website
Fact sheet and video describing sexual
problems and treatment options for
the general population.




Fact sheets about cancer, its effect on
sex and sexuality, and treatment
options




Sexual function screening guidelines
and treatment options for cancer
survivors
National Comprehensive Cancer Network http://www.nccn.org/professionals/physician_gls/
pdf/survivorship.pdf
Recorded talk by sexual health
providers on rediscovering intimacy
after cancer treatment
Cancer Care, in collaboration with National Cancer
Institute, Livestrong, LBBC, Intercultural Cancer
Council, National Coalition for Cancer Survivorship
http://www.cancercare.org/connect_workshops/138-
cancer_survivorship_2008-05-13
Information on vaginal dryness
treatment options for the general
population
North American Menopause Society http://www.menopause.org/docs/for-women/
mndryness.pdf
Online forum to talk to other breast
cancer survivors about sexual concerns
BreastCancer.org http://www.breastcancer.org/tips/intimacy
Finding a sexual health provider American Association of Sexuality Educations,
Counselors, and Therapists
http://www.aasect.org/referral-directory
Finding a sexual health provider Society for Sex Therapy and Research http://www.sstarnet.org/therapist-directory.php
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("vaginal lubricant" OR "vaginal moisturizer" OR "pelvic
floor muscle relaxation" OR "pelvic floor physical therapy"
OR "pelvic floor muscle training" OR "biofeedback" OR
"vaginal dilator" OR "biofeedback" OR "cognitive behavioral
therapy" OR ("sex" AND "therapy") OR "psychotherapy"
OR "sex counseling" OR "patient education" OR "testoster-
one" OR "antidepressant" OR "treatment" OR "flibanserin"
OR "ospemifene" OR "vibrator" OR "vaginal dilator"
OR "DHEA")).
AND (("Sexual Dysfunction, Physiological"[Mesh] OR
"Interpersonal Relations"[Mesh] OR "Sexual Behavior"[-
Mesh] OR "Vaginismus"[Mesh] OR "Coitus"[Mesh] OR
"Libido"[Mesh] OR "Orgasm"[Mesh]) OR ("dyspareunia"
OR "coitus" OR "coital frequency" OR "intercourse fre-
quency" OR "vaginal dryness" OR "sexual lubrication" OR
"vulvovaginal atrophy" OR "libido" OR "sexual function"
OR "sexual dysfunction" OR "sexual interest" OR "sexual
desire" OR "sexual arousal" OR "orgasm" OR "sexual pleas-
ure" OR "sexual dissatisfaction" OR "sex" OR "intimacy"
OR "sexual desire disorder" OR "sexual arousal disorder"
OR "orgasmic disorder" OR "sexual pain disorder")).
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